Lumira Ventures is a venture capital firm that specializes in investing in emerging, mid, and late-stage companies within the healthcare and life sciences sectors. Founded in 2007 and based in Toronto, Ontario, with additional offices in Montreal, Vancouver, and Boston, the firm primarily focuses on biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies. Lumira Ventures typically invests between 5 million and 15 million in North American companies, emphasizing those located in Canada and the United States. The firm is committed to helping its portfolio companies enhance the value of their technology pipelines through active board participation and support in accessing additional funding sources and market opportunities. With a history that includes investments in over 100 healthcare companies, Lumira Ventures currently manages a portfolio of more than 30 active investee companies that aim to address significant unmet needs in the healthcare landscape.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.
OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.
OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.
Deka Biosciences
Series A in 2021
Early stage biotechnology start-up developing next generation cytokine therapeutics
Thryv Therapeutics is a biopharmaceutical company focused on developing therapies for long QT syndrome, a genetic disorder characterized by prolonged ventricular repolarization, which can lead to life-threatening arrhythmias. The company's research centers on SGK-1, a regulator of sodium channels in heart cells, which is implicated in the overactivity associated with long QT syndrome. By targeting this kinase, Thryv aims to address the underlying causes of the disorder and improve treatment options for affected patients. Based in Laval, Canada, the company is committed to advancing its pipeline to enhance patient outcomes in this critical area of cardiovascular health.
BioTheryX, Inc. is a biopharmaceutical company based in Chappaqua, New York, that specializes in the development of therapies for hematological malignancies and other diseases. The company focuses on restoring protein homeostasis through innovative approaches such as Protein Homeostatic Modulators, which are small molecular glue cereblon binders with significant therapeutic potential. Additionally, BioTheryX is advancing targeted protein degradation technologies, including PROTACs, which utilize dual ligands to facilitate the degradation of specific proteins. The company also offers BTX-A51, an oral small molecule that acts as a multi-kinase inhibitor to target leukemic stem cells and suppress key oncogenic gene transcription. Founded in 2007, BioTheryX aims to expedite the delivery of effective therapies to patients with unmet medical needs by leveraging enhanced biology-driven models and clinically proven translational approaches.
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.
AmacaThera Inc. is a biotechnology company based in Toronto, Canada, founded in 2016. The company specializes in developing and commercializing an innovative injectable hydrogel platform technology designed for various medical applications. This technology aims to enhance therapeutic delivery and improve patient outcomes across multiple healthcare sectors.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
Notch Therapeutics Inc., an immune cell therapy company, develops gene-edited allogenic T cell therapies for the treatment of cancer. The company offers induced pluripotent stem cell (iPSC) AlloCAR therapy products for non-Hodgkin lymphoma, leukemia, and multiple myeloma. Notch Therapeutics Inc. was incorporated in 2018 and is based in Toronto, Canada.
XyloCor Therapeutics is a biopharmaceutical company focused on developing gene therapies for cardiovascular diseases, particularly for patients with advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company is working on innovative treatments such as XC001, an investigational gene therapy aimed at patients suffering from refractory angina who have limited treatment options. Another product in development, XC002, targets the regeneration of cardiac tissue in individuals with impaired heart function due to previous heart attacks and heart failure. XyloCor's therapies aim to stimulate the formation of new coronary blood vessels, providing essential blood supply to areas of the heart that are currently underserved, ultimately offering a more effective and less painful solution for those affected by these serious conditions.
Cyrano Therapeutics, Inc., founded in 2014 and headquartered in Washington, D.C., develops therapeutic solutions aimed at addressing taste and smell disorders. The company's primary offering is an intranasal product, CYR-001, which repurposes the approved molecule Theophylline to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, the treatment demonstrated significant efficacy, with eight out of ten patients showing notable improvements within two weeks and no reported side effects. In addition to the therapy, Cyrano Therapeutics provides a diagnostic kit to assess and quantify the severity of sensory loss, which can assist healthcare providers, particularly otolaryngologists, in managing care for affected individuals, including cancer patients undergoing chemotherapy who may experience sensory changes.
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
IMV Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies and vaccines for infectious diseases, including COVID-19. Utilizing its proprietary delivery platform, the company targets immune cells within the human body to enhance their ability to attack cancer cells. Its lead candidate, DPX-Survivac, is a targeted T cell therapy that has shown promise in multiple Phase 1 and 1b trials for late-stage ovarian cancer and relapsed/refractory DLBCL. DPX-Survivac is currently undergoing Phase 2 clinical trials across six cancer types and is being evaluated in combination with Keytruda. IMV is also progressing with a DPX-based vaccine for COVID-19, developed in collaboration with experts in infectious diseases, and is working on a vaccine targeting the respiratory syncytial virus strain A. Founded in 2000 and based in Dartmouth, Canada, the company was previously known as Immunovaccine Inc. before rebranding in 2018.
IMV Inc Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company’s DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. IMV Inc has advanced two DepoVax-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious disease pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. IMV Inc has key partnerships in the animal health sector including an agreement with Pfizer Animal Health.
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance, enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens.
AmacaThera Inc. is a biotechnology company based in Toronto, Canada, founded in 2016. The company specializes in developing and commercializing an innovative injectable hydrogel platform technology designed for various medical applications. This technology aims to enhance therapeutic delivery and improve patient outcomes across multiple healthcare sectors.
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraines. The company's primary product candidate, STS101, is a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine mesylate. This medication is designed for self-administration using a pre-filled, single-use nasal delivery device. Currently, STS101 is undergoing Phase III clinical trials, marking a significant step in its development process. Founded in 2016 and based in South San Francisco, California, Satsuma Pharmaceuticals aims to provide effective solutions for individuals suffering from acute migraine attacks.
Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
enGene, Inc. is a biotechnology company based in Vancouver, Canada, focused on developing a mucosal immunotherapy platform aimed at treating inflammatory bowel disease and diabetes. The company utilizes a non-integrating biopolymer-based nucleotide delivery technology, which allows for the localized delivery of immune-modulating proteins to the intestinal mucosa. This innovative approach targets diseases affecting mucosal tissues, including those in the gastrointestinal tract, lung, and bladder, while also facilitating systemic protein release to address conditions such as diabetes, anemia, and hemophilia. enGene’s platform technology supports the induction or suppression of protein expression levels, enabling improved physiological insulin secretion in diabetes patients. The company has established a strategic alliance with Takeda Pharmaceutical Company Ltd. since its founding in 1999.
Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.
Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections.Gladius is a disruptive platform technology play, capable of developing multiple novel drug candidates
Pediapharm is the ONLY pediatric specialty pharmaceutical company in Canada, providing sales and marketing expertise for the pediatric market segment. Through its network of 2,000 pediatricians and 5,000 pharmacies, Pediapharm's key objectives are to partner with healthcare entities around the world and bring NEW innovative or existing OTC and Rx pediatric products to the Canadian market.
Endotronix Inc. specializes in the development of miniaturized, wireless, and implantable pressure sensors designed for interventional cardiovascular procedures. The company focuses on hemodynamic monitoring technologies that enable the early detection of worsening heart failure. Its innovative platform includes a cloud-based disease management system and an outpatient hemodynamic management solution featuring an implantable wireless pulmonary artery sensor. Founded in 2007, Endotronix is headquartered in Lisle, Illinois.
KisoJi Biotechnology
Series A in 2018
KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.
KalGene Inc. is a Canadian company focused on developing precision medicine aimed at treating Alzheimer's disease and cancer. Established in 2006 and based in Candiac, the company collaborates with leading clinician-scientists and academic institutions across North America and Europe. KalGene specializes in creating targeted therapeutics and companion diagnostics that utilize a personalized medicine approach. This methodology seeks to predict patient responses to specific therapies based on their unique biological profiles, allowing for tailored treatment plans. By emphasizing individualized care, KalGene's therapeutics aim to improve both clinical outcomes and overall quality of life, while addressing safety concerns associated with traditional treatments.
Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.
KisoJi Biotechnology
Venture Round in 2018
KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.
Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.
KalGene Inc. is a Canadian company focused on developing precision medicine aimed at treating Alzheimer's disease and cancer. Established in 2006 and based in Candiac, the company collaborates with leading clinician-scientists and academic institutions across North America and Europe. KalGene specializes in creating targeted therapeutics and companion diagnostics that utilize a personalized medicine approach. This methodology seeks to predict patient responses to specific therapies based on their unique biological profiles, allowing for tailored treatment plans. By emphasizing individualized care, KalGene's therapeutics aim to improve both clinical outcomes and overall quality of life, while addressing safety concerns associated with traditional treatments.
Engage Therapeutics is a biopharmaceutical company based in Summit, New Jersey, focused on developing innovative rescue therapies for individuals experiencing uncontrolled epileptic seizures. The company's lead investigational product, Staccato® alprazolam, is a handheld drug-device combination that utilizes an FDA-approved delivery system along with the approved medication alprazolam. This product aims to provide a rapid response to active and acute seizures. Preliminary results from a Phase 2a proof of concept study indicated that Staccato alprazolam effectively reduced seizures in a photosensitivity model. Engage Therapeutics plans to advance this product through clinical development using the 505(b)(2) regulatory pathway. The company operates as a subsidiary of UCB SA.
Stellar Biotechnologies, previously an independent biotechnology company, specialized in the research, development, and commercialization of keyhole limpet hemocyanin (KLH) protein, primarily serving the immunotherapy and immunodiagnostic markets. Based in Port Hueneme, California, the company offered KLH in various grades and formulations, catering to the needs of biotechnology and pharmaceutical firms, academic institutions, clinical research organizations, and research centers across Europe, North America, and Asia. KLH is an immune-stimulating protein utilized in the production of immunotherapies and as a carrier molecule in diagnostic products. In June 2019, Stellar Biotechnologies was acquired by Edesa Biotech Inc. through a reverse merger transaction, integrating its expertise in KLH protein with Edesa's focus on developing innovative treatments for dermatological and anorectal diseases.
Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. The initial focus is on developing novel, safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. Edesa Biotech’s lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.
Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.
KisoJi Biotechnology
Series A in 2016
KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.
Endotronix Inc. specializes in the development of miniaturized, wireless, and implantable pressure sensors designed for interventional cardiovascular procedures. The company focuses on hemodynamic monitoring technologies that enable the early detection of worsening heart failure. Its innovative platform includes a cloud-based disease management system and an outpatient hemodynamic management solution featuring an implantable wireless pulmonary artery sensor. Founded in 2007, Endotronix is headquartered in Lisle, Illinois.
Opsens Inc. specializes in the development, manufacture, installation, and sale of fiber optic sensors, catering to various sectors including interventional cardiology, oil and gas, and industrial applications. The company operates through two primary segments: Medical and Industrial. The Medical segment focuses on physiological measurements such as fractional flow reserve (FFR) and provides miniature optical sensors for pressure and temperature measurement, essential for coronary artery stenosis diagnosis. It also licenses its optical sensor technology. The Industrial segment creates fiber optic sensing solutions applicable in diverse fields such as life sciences, energy, defense, and civil engineering. Notable products include OptoWire, an advanced optical pressure guidewire for coronary artery disease, and a range of fiber optic sensors for measuring temperature, pressure, strain, and displacement. Opsens distributes its products through a direct sales force and partnerships with distributors in the United States, Japan, Canada, and other international markets. Headquartered in Québec, Canada, Opsens is recognized for its high-accuracy sensors that are particularly beneficial in clinical environments.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.
This national mobile wellness rewards initiative harnesses the public’s affinity for popular loyalty points, the convenience of smart phone technology and Canadians’ natural desire to lead healthier lives. It is this unique combination that results in such a powerful “nudge” platform – in support of a healthier
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
First Aid Shot Therapy offers a market segment defined as clinical beverages designed to address acute or chronic clinical needs. It offers a range of easy-to-swallow, single-dose products that provide fast-acting relief for most common everyday symptoms; hangover, pain, sleep, cold, allergy, and heartburn. The company was founded in 2010 and is headquartered in Burlingame, California.
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections.Gladius is a disruptive platform technology play, capable of developing multiple novel drug candidates
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.
Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).
Vascular Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutics for treating patients with type 1 and type 2 diabetes. It focuses on the development of VPI-2690B, a subcutaneously administered monoclonal antibody that is stimulated by hyperglycemia for the treatment of diabetic nephropathy. The company was founded in 2005 and is based in Research Triangle Park, North Carolina.
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
enGene, Inc. is a biotechnology company based in Vancouver, Canada, focused on developing a mucosal immunotherapy platform aimed at treating inflammatory bowel disease and diabetes. The company utilizes a non-integrating biopolymer-based nucleotide delivery technology, which allows for the localized delivery of immune-modulating proteins to the intestinal mucosa. This innovative approach targets diseases affecting mucosal tissues, including those in the gastrointestinal tract, lung, and bladder, while also facilitating systemic protein release to address conditions such as diabetes, anemia, and hemophilia. enGene’s platform technology supports the induction or suppression of protein expression levels, enabling improved physiological insulin secretion in diabetes patients. The company has established a strategic alliance with Takeda Pharmaceutical Company Ltd. since its founding in 1999.
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.
Corvia Medical, Inc. is a medical device company specializing in the development of structural heart devices aimed at treating heart failure. The company's primary innovation is the InterAtrial Shunt Device (IASD), a transcatheter device designed to address diastolic heart failure (DHF), also referred to as heart failure with preserved ejection fraction (HFpEF). The IASD system works by creating a small opening between the left and right atria, which helps to lower elevated left atrial pressure, a main contributor to DHF symptoms. Founded in 2009 and based in Andover, Massachusetts, Corvia Medical was previously known as DC Devices Inc. and rebranded in June 2015. Through its innovative approach, the company aims to alleviate symptoms and enhance the quality of life for patients affected by heart failure.
Spinal Kinetics LLC is a medical device company based in Sunnyvale, California, specializing in the design and development of non-fusion motion preservation systems for degenerative diseases of the cervical and lumbar spine. Founded in 2003, the company offers the M6-C artificial cervical disc and the M6-L artificial lumbar disc, both designed to replicate the anatomical and biomechanical properties of natural intervertebral discs. The M6 products incorporate an artificial nucleus and annulus to mimic a natural disc's structure. Spinal Kinetics distributes its products through a network of partners across multiple countries, including Australia, Canada, and various European nations. As a subsidiary of Orthofix Medical Inc., Spinal Kinetics collaborates with spine surgeons to advance innovative treatment options in spinal health.
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.
Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company based in Victoria, British Columbia, that specializes in developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily focused on the investigational drug voclosporin, which is being developed for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia aims to address the needs of targeted patient populations in both the United States and China through its innovative therapeutic approaches.
enGene, Inc. is a biotechnology company based in Vancouver, Canada, focused on developing a mucosal immunotherapy platform aimed at treating inflammatory bowel disease and diabetes. The company utilizes a non-integrating biopolymer-based nucleotide delivery technology, which allows for the localized delivery of immune-modulating proteins to the intestinal mucosa. This innovative approach targets diseases affecting mucosal tissues, including those in the gastrointestinal tract, lung, and bladder, while also facilitating systemic protein release to address conditions such as diabetes, anemia, and hemophilia. enGene’s platform technology supports the induction or suppression of protein expression levels, enabling improved physiological insulin secretion in diabetes patients. The company has established a strategic alliance with Takeda Pharmaceutical Company Ltd. since its founding in 1999.
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company based in Victoria, British Columbia, that specializes in developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily focused on the investigational drug voclosporin, which is being developed for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. Aurinia aims to address the needs of targeted patient populations in both the United States and China through its innovative therapeutic approaches.
Corvia Medical, Inc. is a medical device company specializing in the development of structural heart devices aimed at treating heart failure. The company's primary innovation is the InterAtrial Shunt Device (IASD), a transcatheter device designed to address diastolic heart failure (DHF), also referred to as heart failure with preserved ejection fraction (HFpEF). The IASD system works by creating a small opening between the left and right atria, which helps to lower elevated left atrial pressure, a main contributor to DHF symptoms. Founded in 2009 and based in Andover, Massachusetts, Corvia Medical was previously known as DC Devices Inc. and rebranded in June 2015. Through its innovative approach, the company aims to alleviate symptoms and enhance the quality of life for patients affected by heart failure.
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.
Usystems is engaged in the design, development, manufacturing, and marketing of advanced ultrasound systems and software aimed at aiding radiologists in the detection of breast cancer in women with dense breast tissue. In addition to its focus on medical technology, the company is dedicated to creating high-quality racking enclosures and cooling products that significantly lower noise, heat, and operational costs in data centers and office environments. Usystems employs innovative design principles and state-of-the-art manufacturing processes to achieve these goals, reflecting a commitment to excellence and efficiency in both healthcare and data management solutions.
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.